The BIGGEST question over the past few weeks has been the
The BIGGEST question over the past few weeks has been the R/S and let me address it here since some of my fellow investors have been constantly asking about it.
Let's say a CEO has around 45-50 Mn. shares and an Investor (let's assume a name - AB) had around 100,000 shares.
In March-April 2018, CEO could have sold them at around $2.5-$3 each and potentially made around $100-120 Mn. while AB may have sold his 100k shares and made around $250-$300k at that time.
Question: Why didn't they do that?
Answer: CEO wants to be a Billionaire and AB wants to be a millionaire which couldn't happen with the stock price of $2-3 at that time.
Fast forward.....Oct'2018
R/S is announced and some of the investors including AB have serious questions regarding the R/S stating that CEO and other big investors holding millions of shares will be less impacted by the R/S and the smaller investors like AB having (100k or less) will just be left with nothing (very few shares) if 20:1 or 40:1 split is executed.
Let's assume there's a 20:1 R/S, how will it impact the CEO, AB and other investors. Say the stock price is around 30 cents and a 20:1 R/S is applied, the NASDAQ uplist price will be $6 and CEO will have around 2.5 Mn. shares and AB will have 5000 shares. At a share price of $6, CEO's total share value will be around $15 Mn. (it was $100 Mn+ in April'18) and AB's share value will be around $30,000 (it was around $250k+ in April'18).
Now, time for some hard questions.....
Will the CEO not try to avoid the R/S at 1:20 and grow the share price higher organically?
Will the CEO be happy with $15 Mn. worth of shares at $6 each? Remember, if he had to make just $100Mn. from this venture, he could have done that in April'2018.
Why didn't he sell at $2.5-$3 price even though he could have made a lot of money? It's simple, he wants the share price to be much higher in future at $10/25/50/100+ to get a much greater return.
The investors who have been questioning the R/S need to think/calculate where the CEO himself stands after the R/S. You'll get your answers very very easily.
PS: There are around 11 million Millionaires and around 540 Billionaires in the US and it's not easy to become any of them. AB will be a millionaire one day with 100k shares and the CEO will be a Billionaire at that time.
Cheers!!
10
TON Strategy Co. (TONX) Stock Research Links
Cheers!!
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...
Continue Reading
No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...
Continue Reading
Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...
Continue Reading
What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...
Continue Reading
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Breaking Ground on a Massive Energy Undertaking Well, folks, Black Bayou's finally breaking ground on their colossal gas storage project in Cameron Parish, Louisiana. They're not just playing around—this thing's set to be a juggernaut, with an imposing 44.4 Bcf of working gas capacity nestled right on top of the Black Bayou salt dome. Talk about marking territory, huh?...
Continue Reading
A New Gadget for the Diehard Fan Fanatics, gather 'round. There's an innovation rolling out that's looking to marry the good old alarm clock radio with the rush of game day fever! Over in Pittsburgh, an inventor's cooking up something that every loyal sports fan might soon find irresistible—a Sports Clock Radio, bringing the stadium experience to your living room or...
Continue Reading
Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...
Continue Reading
The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...
Continue Reading
Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...
Continue Reading
Top 5 Most Recently Viewed Articles
Investors Targeting Crocs Encouraged to Join Class Action Faruqi & Faruqi, LLP, a prominent name in securities litigation, is reaching out to investors who have experienced significant losses in Crocs stock to participate in an emerging federal class action lawsuit. The firm is particularly concerned with those who incurred losses exceeding $50,000. The deadline to assume...
Continue Reading
Chaoyang: A Tapestry of Global Life Taking a stroll through Beijing's Chaoyang district, you'd catch more than just a glimpse of its soaring skyscrapers or riverside parks—you're stepping into a melting pot of cultures and modern business ethos. It’s not puffery when they say this district marries the world’s diversified cultures with dynamic business environments;...
Continue Reading
Foot Locker on the Path to Recovery Recent analysis by Needham's analyst Tom Nikic illustrates a promising outlook for Foot Locker, Inc. (NYSE: FL), highlighting how the company is positioned for earnings recovery in the coming year. The strengthened partnership with Nike, along with growth in non-Nike brands, and recent investments in selling, general and administrative...
Continue Reading
The Rising Trend of Milking Automation Market The milking automation market is currently experiencing a significant transformation, with estimates projecting a growth to USD 3.68 billion by 2030. This steady rise reflects a robust CAGR of 7.1% from an initial valuation of USD 2.61 billion. Factors driving this expansion include increasing demand for milk, labor shortages...
Continue Reading
Immatics Updates on ACTengine® IMA203 for Melanoma Patients Overview: Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in the development of T cell-redirecting immunotherapies, has recently announced significant advancements in its clinical trial of ACTengine® IMA203. The focus of this update is on the therapy's application in...
Continue Reading